Open-label, Dose-escalating Trial to Evaluate the Tolerability, Toxicity, Safety, Pharmacokinetics, Pharmacodynamics and Activity of Volasertib Added to the Standard Intensive Salvage Chemotherapy Regimen With Liposomal Daunorubicine, Fludarabine and Cytarabine (DNX-FLA) Followed by Fludarabine and Cytarabine (FLA) in Children From 3 Months to Less Than 18 Years of Age With Acute Myeloid Leukaemia After Failure of the Front-line Therapy

This is an open-label, dose-escalating trial to evaluate the MTD and/or dose to be used for further development by evaluation of DLT in course 1 and the safety of volasertib when added to standard intensive salvage chemotherapy with DNX-FLA in paediatric patients with AML after failure of first-line therapy. Furthermore, data on efficacy and PK/PD of volasertib in paediatric patients with AML when added to standard intensive salvage chemotherapy will be collected.

Start Date01 Nov 2016

Sponsor / Collaborator

Boehringer Ingelheim GmbH

NCT02757248

/ WithdrawnPhase 1IIT

A Phase I Trial of Volasertib Plus Romidepsin in Patients With Relapsed/Refractory Peripheral T Cell and Cutaneous T Cell Lymphoma

This is a phase I study of the combination of volasertib and romidepsin in patients with relapsed/refractory peripheral T cell lymphoma (PTCL) or stage IIB-IV cutaneous T cell lymphoma (CTCL). This study will determine the maximum tolerated dose (MTD) of this combination by treating cohorts of patients at a certain dose combination. The investigators will use a Bayesian design to determine the dose combination for the next cohort of patients and to determine the MTD. Overall response rate as well as adverse events will be monitored and reported.

Start Date01 Nov 2016

Sponsor / Collaborator

Duke University

[+2]

NCT02527174

/ WithdrawnPhase 1IIT

A Phase I Study of Volasertib Combined With Standard Induction Chemotherapy for Previously Untreated Patients With Acute Myeloid Leukemia (VIAC)

This is a Phase I clinical trial to determine the maximum tolerated dose (MTD) of the polo-like kinase-1 inhibitor volasertib which can be safely combined with idarubicin plus cytarabine induction chemotherapy for previously untreated patients with acute myeloid leukemia. (AML).

Start Date01 Nov 2016

Sponsor / Collaborator

University of Alberta

100 Clinical Results associated with Volasertib

100 Translational Medicine associated with Volasertib

100 Patents (Medical) associated with Volasertib

270

Literatures (Medical) associated with Volasertib

01 Feb 2026·AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

PLK1 inhibition by volasertib suppresses key transcriptional regulators underlying fibroblast activation and pulmonary fibrosis

Article

Author: Jegga, Anil G. ; Kasam, Rajesh K. ; Lawson, Ryan ; Madala, Satish K. ; Patel, Pradeep K. ; Ediga, Harshavardhana H. ; Singh, Priyanka

Excessive proliferation, impaired apoptotic clearance, and extracellular matrix (ECM) production are pathological features of fibroblast activation that together result in scar tissue formation in pulmonary fibrosis. This study identifies the previously unrecognized role for the WT1-MYCN-PLK1 axis in promoting fibroblast activation and highlights the therapeutic potential of PLK1 inhibition with volasertib as an antifibrotic strategy.

08 Jan 2026·Anti-Cancer Agents in Medicinal Chemistry

Discovery of Small Molecule Inhibitors against Polo-Like Kinase 1 Targeting Breast Cancer

Article

Author: Manickam, Venkatraman ; Munieswaran, Gayatri

Introduction::

The polo-like kinase-1 (PLK1) plays a significant role in cell cycle regulation and proliferation; upon dysregulation, PLK1 activates different oncogenic pathways that lead to breast cancer. Therefore, targeting the PLK1 protein on the kinase domain prevents the possibility of tumor development.

Methods::

A machine learning model was developed to screen small molecules against PLK1 using a cancer bioassay dataset. The binding affinity and structural integrity of the complex were assessed using molecular docking and dynamic studies. In vitro evaluation was then performed for the screened compound against the SKBR3 cell line.

Results::

The research findings highlighted the silymarin flavonoid to have a greater binding energy with PLK1 (-9.2 Kcal/mol) than other molecules (above -8.5 Kcal/mol). Additionally, the molecular dynamics simulation showed silymarin to be more stable, less flexible, and more compact with PLK1. Further, the binding free energy revealed silymarin to be more stable with PLK1 (-13.25 kcal/mol) than volasertib (-2.87 kcal/mol). The IC50 value of silymarin was found to be 95.76 μg/mL, inducing apoptosis on the SKBR3 cell line.

Discussion::

Despite PLK1 being predicted as a potential oncogenic target, the treatment choices were limited. A cheminformatics approach was utilized for screening inhibitors against PLK1. The in silico and in vitro evaluations indicated that silymarin effectively inhibited the PLK1 protein in breast cancer.

Conclusion::

These research findings established silymarin as a potential alternative drug targeting PLK1, which is highly expressed in HER2-positive breast cancer, and modulates the oncogenic processes not just in breast cancer, but also in other cancers.

01 Jan 2026·ADVANCED MATERIALS

Neutrophil/Leukemia‐Tropic Dual‐Drug Nanomedicine Potentiates the Treatment of Acute Myeloid Leukemia

Article

Author: Zhai, Zhenzhen ; Zhong, Zhiyuan ; Xu, Yang ; Li, Jiaying ; An, Jingnan ; Sun, Huanli ; Yue, Shujing ; Zhao, Cenzhu

Abstract:

Acute myeloid leukemia (AML) poses severe clinical challenges due to its heterogeneity and the scattered nature of therapeutic targets. Moreover, suboptimal drug delivery to the bone marrow, combined with the protective effects of the niche that shelters residual leukemia cells, frequently underlies chemotherapy failure and relapse. Here, a neutrophil/leukemia‐tropic polymersome vincristine/volasertib dual‐drug nanoformulation (NLP‐Vi/Vo) is reported to selectively bind to leukemia cells and neutrophils, and to ratiometrically release clinical chemotherapeutics and a polo‐like kinase 1 inhibitor, thereby potentiating the treatment of AML. NLP‐Vi/Vo induces synergistic anti‐AML effects by sensitizing AML to chemotherapy, and homes to bone marrow by hitchhiking on neutrophils, cooperatively depleting leukemia in both the bloodstream and bone marrow. NLP‐Vi/Vo shows excellent therapeutic efficacy in malignant murine AML and human AML xenograft models. Collectively, neutrophil/leukemia‐directing dual‐drug nanomedicines offer a promising treatment strategy for AML.

News (Medical) associated with Volasertib

30 Jul 2025

·endpoints.news

Cardiff’s targeted therapy shows early promise in KRAS-mutated colorectal cancers

Cardiff Oncology reported that adding a high dose of its experimental candidate onvansertib to standard treatments shrank tumors in a mid-stage study of patients with KRAS-mutated colorectal cancer. The Phase 2 study shows that there was a 19-percentage point difference in the confirmed overall response rate between patients in the experimental arm and those who received standard treatments alone. The company’s lead asset blocks a key cell growth protein called PLK1. Cardiff is studying onvansertib across the nearly half of all metastatic colorectal cancers that harbor KRAS mutations. Unlike a KRAS inhibitor such as Amgen’s Lumakras, which can only address a specific KRAS mutation, Cardiff hopes its drug can be used to treat the range of KRAS-mutated colorectal cancers. In the trial, 110 patients received chemotherapy and bevacizumab alone or alongside a 20 mg or 30 mg dose of Cardiff’s drug as a first-line treatment. Cardiff reported that 49% of patients who received the high dose of onvansertib had a confirmed response, compared to 30% of those who received placebo. Among patients who received the 20 mg dose, 42% responded to treatment. However, Cardiff’s stock $CRDF fell around 25% at market open Wednesday. It had reported an earlier cut of data in December, showing a 31-point difference between the response rate of the high-dose arm and the placebo group — but in fewer patients. Jefferies analyst Maury Raycroft called Tuesday’s readout “encouraging” in a note to investors, but noted more data were needed around the durability of responses. Cardiff CEO Mark Erlander told Endpoints News that pending discussions with the FDA, the company expects to move the 30 mg dose forward into late-stage studies. Cardiff is planning to give another update on the mid-stage study early next year, and then it hopes to start a pivotal study next year as well. Erlander said a key feature of Cardiff’s drug is that it targets PLK1 very specifically. Previous iterations of PLK inhibitors, such as Boehringer Ingelheim’s volasertib, were not as specific and therefore led to substantial toxicities. In the updated data shared Tuesday, Cardiff reported that the drug combination was “well-tolerated and there were no major or unexpected toxicities observed,” though some patients experienced neutropenia associated with onvansertib. Cardiff chief medical officer Roger Sidhu told Endpoints that rates of adverse events were comparable across the control and treatment arms. Outside of Cardiff, few are studying drugs aimed at PLK1. Raycroft wrote in June that Cardiff is working in an arena that “has seen little innovation and lacks major late-stage competitors,” as most others are targeting narrow mutation subpopulations. Editor’s note: Cardiff’s stock move was updated.

Phase 2Clinical Result

30 Aug 2024

·endpts.com

J&J's human resources leader to retire; Amgen becomes the newest pharma with a top AI exec

→ Kristen Mulholland will take over for the retiring Peter Fasolo as chief human resources officer at J&J on Oct. 1. “Peter has led J&J’s talent strategy for the past 16 years including remarkable leadership through the global pandemic and the separation of our consumer health business,” CEO Joaquin Duato said in a statement . “He leaves a legacy of strong leaders, deep bench strength and an inclusive, caring and patient-focused culture.” Fasolo is a Bristol Myers Squibb HR vet who left J&J to become chief talent officer for KKR , only to return in 2010. Mulholland started at J&J in 2005 and has spent nearly five years as head of human resources, global total rewards & enterprise HR functions. → Just do it: Amgen technology chief David Reese said in a LinkedIn post that the pharma giant has appointed Sean Bruich as SVP of artificial intelligence and data. Bruich moves into the pharma world after an 11-year run with Nike , where he vaulted to global VP, insights, data science & analytics. This is the second high-level AI hire by a major pharma in as many weeks — Pfizer just welcomed Berta Rodriguez-Hervas as its new chief AI and analytics officer. → In its biggest personnel news since Doug Williams ’ resignation , Sana Biotechnology has poached Dhaval Patel from UCB as the Seattle biotech awaits data readouts for its CD19-targeted allogeneic CAR-T therapy in a host of indications. Patel had a 10-year career with Novartis before he held the CSO post at UCB for nearly seven years, and he’ll have the same responsibilities at Sana under CEO Steve Harr . Sana said in its second-quarter update that the goal is to reveal data for SC291 in B cell malignancies — and such autoimmune diseases as lupus nephritis, extrarenal lupus and ANCA-associated vasculitis — sometime this year. “His expertise in immunology and autoimmune diseases make[s] him ideally suited to help advance our clinical pipeline,” Harr said in a statement . → Brian Di Donato , the CFO and head of strategy at Immunocore since May 2020 , is stepping down “at the end of the year” to take the CEO job at an unnamed San Diego biotech. Di Donato was the finance leader for Achillion when Alexion scooped it up for $930 million, and he’s also a board member at Jim Wilson joint iECURE , where ex-Achillion chief Joseph Truitt is CEO. → Telix Pharmaceuticals has separated its business into four separate entities: Telix Therapeutics , Telix Precision Medicine (diagnostics), Telix Lightpoint (medtech, from its acquisition of Lightpoint Medical ) and Telix Manufacturing Solutions . With these changes in place, Telix has tapped Richard Valeix as CEO of Telix Therapeutics, Kevin Richardson as Telix Precision Medicine’s chief executive, and Raphael Ortiz as CEO of Telix International . Christian Behrenbruch ’s title has been slightly modified to group CEO. Telix had hoped to join the Nasdaq in June with an IPO around the $200 million mark, but the Melbourne biotech made a gametime decision to pull those plans . → Cambridge, MA-based neuro player Cognito Therapeutics has promoted Christian Howell to CEO. Brent Vaughan had been running Cognito since 2020 after co-founding and leading the autism diagnostic specialist Cognoa , and he hired Howell as his chief commercial officer last October. Howell had a long career with Medtronic and then joined Aetion , where he was elevated to SVP and general manager of the emerging channels group (medical device, diagnostics, digital health, and government) in April 2023. → Elsewhere, Endo is also losing its president and CEO Blaise Coleman . Board member Scott Hirsch will serve in the interim as the company searches for a permanent successor. Hirsch joined Endo’s board in April, around the same time that the company sued the FDA over its approval of a generic version of Endo’s drug Adrenalin . Hirsch is the former CEO of Solta Medical and also held the roles of president of Ortho Dermatologics and CBO of Bausch Health / Bausch + Lomb . → Thomas Bock has handed in his resignation as CEO of Notable Labs , and CSO Joseph Wagner will take over the top spot on an interim basis. This isn’t uncharted territory for Wagner: He’s the former CEO of Oncocyte (2011-15) and Canadian I/O biotech BriaCell Therapeutics (2015-16). Notable Labs merged with VBL Therapeutics in February 2023 and will start enrolling patients in its Phase 2 study of the ex- Boehringer Ingelheim drug volasertib for acute myeloid leukemia “in the coming months,” the company said in July. → Delfi Diagnostics marked the beginning of the year with a new CEO it hired away from Illumina . Now, the competitor to Grail has brought on Thomas Russo as finance chief. Russo served in the same role at Icosavax and Assembly Biosciences . During his time at Icosavax, Russo helped with the company’s growth until its $838 million upfront acquisition by AstraZeneca . → Marea Therapeutics , the Third Rock upstart led by ex- Graphite Bio CEO Josh Lehrer , has selected Ian Clements as CFO. Clements resigned from the same post at Livmarli maker Mirum Pharmaceuticals in May 2023 after four years overall with the company, and he’s the ex-VP of investor relations for Dermira . Marea launched in June with $190 million in “combined Series A and B” funding, testing an ex-Novartis monoclonal antibody that targets ANGPTL4 in adults with metabolic dysfunction. → With ex- Synlogic CEO Aoife Brennan at the controls, a seemingly rejuvenated Eliem Therapeutics has named Brett Kaplan as COO and Nishi Rampal as SVP, clinical development. Kaplan had been president and chief financial & corporate development officer for epigenetic editing upstart Chroma Medicine , and he was also the finance chief at Prevail until Eli Lilly bought the gene therapy biotech for $1 billion. An Alexion vet, Rampal also handled the role of global development and strategy lead for the neuromyelitis optica spectrum disorder (NMOSD) treatment Uplizna as an executive director with Horizon /Amgen. Eliem’s hunt for strategic alternatives ended with the acquisition of Tenet Medicines and its anti-CD19 antibody budoprutug , once known as TNT119 . → Backed by RA Capital and Forbion , Navigator Medicines disclosed its $100 million Series A this week and the recruitment of Dana McClintock as CMO. McClintock spent six years in the same position at Alladapt Immunotherapeutics and was global head of the Office of I2O Innovation for Genentech . Navigator also said that Forbion general partner Wouter Joustra and RA Capital managing director Andrew Levin have made their way to the board of directors. → Alex Bastian has been named VP, commercial strategy at Swiss-based Memo Therapeutics , reuniting with CEO Erik van den Berg . Toward the end of van den Berg’s tenure as CEO of AM-Pharma , Bastian was the Dutch biotech’s VP, commercial & patient access. He also worked for Galapagos as VP, head of value & market access. → Structure Therapeutics , one of many biotechs developing a GLP-1 drug for obesity, has elected ex- Shire CEO Angus Russell to the board of directors. The 68-year-old Russell has chaired the board at Daxxify maker Revance Therapeutics since 2014 and has a board seat at Lineage Cell Therapeutics . → Ex- Vividion CEO Jeff Hatfield has joined the board of directors at Gate Bioscience , a California drug developer that launched last November with a $60 million Series A from several blue-chip investors. Hatfield chairs the board at Vividion and Rome Therapeutics . → Opna Bio has made room for Inozyme co-founder and former CEO Axel Bolte on the board of directors. The South San Francisco biotech also announced that it had dosed the first patient in a Phase 1 trial of its multiple myeloma candidate OPN-6602 and appointed Myeloma Investment Fund managing director Stephanie Oestreich as a board observer.

Executive ChangePhase 1AcquisitionIPO

29 Aug 2024

·www.globenewswire.com

Notable Labs to Present Data on September 4th at SOHO 2024

Society of Hematologic Oncology (SOHO) session to highlight volasertib program Phase 2 volasertib AML program expected to begin in the coming months FOSTER CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs” or the “Company”), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), announced that the Company will present an overview of the Phase 2 program and additional data from preclinical studies evaluating volasertib for acute myeloid leukemia (AML) at the twelfth annual meeting of the Society for Hematologic Oncology (SOHO 2024), being held from September 4th-7th 2024. Presentation details: Poster:Revival of the polo-like kinase 1 (PLK1) inhibitor volasertib in relapsed/refractory acute myeloid leukemiaAuthors:G. Michelson, S. Houston, C. Leonardi, C. Gu, M. Lacher, and J. WagnerPoster Session:Wednesday, September 4th at 6:15 PM CDT About Volasertib Volasertib is a PLK-1 inhibitor with demonstrated activity in AML and other tumor types with significant unmet medical need, including solid tumors. Building on the performance of volasertib on PMP, an important and proprietary step during Notable’s targeted in-licensing strategy and decision making, Notable will utilize its PMP to predict volasertib-responsive patients prior to their treatment, with the goal of selectively enrolling and treating those predicted responders, increasing volasertib’s response rates and overall patient outcomes, and fast-tracking volasertib’s remaining clinical development. Volasertib was originally developed and manufactured by Boehringer Ingelheim and previously granted Breakthrough Therapy Designation by the FDA. Notable in-licensed volasertib and has exclusive worldwide development and commercialization rights, except for certain rare pediatric cancers. About Notable Labs, Ltd. Notable Labs, Ltd. is a clinical-stage platform therapeutics company developing predictive medicines for patients with cancer. Through its proprietary Predictive Medicine Platform (PMP), Notable aims to predict whether or not a patient is likely to respond to a specific therapeutic. The PMP is designed to identify and select clinically responsive patients prior to their treatment, potentially fast-tracking clinical development. By continually advancing and expanding the reach of the PMP across diseases and predicted medical outcomes, Notable aims to be the leader in predictive medicine and revolutionize the way patients seek and receive treatments that work best for them. Notable believes the use of PMP also provides the Company with a more targeted and de-risked in-licensing strategy to deliver a product’s medical impact and commercial value faster, with a greater likelihood of success, than traditional drug development. By transforming historical standards of care, Notable aims to create a dramatically positive impact for patients and the healthcare community. Notable is headquartered in Foster City, California. Learn more at the Company’s website: https://notablelabs.com/ and follow us @notablelabs. Forward Looking StatementsThis press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied statements regarding Notable’s future operations and goals; the potential benefits of any therapeutic candidates or platform technologies of Notable; the timing of any clinical milestones of Notable’s therapeutic candidates; the cash runway of the Company; and other statements that are not historical fact. All statements other than statements of historical fact contained in this communication are forward-looking statements. These forward-looking statements are made as of the date they were first issued, and are based on the then-current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Notable’s control. Notable’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to (i) uncertainties associated with Notable’s platform technologies, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the commencement, enrollment and completion of clinical trials; (ii) risks related to the inability of Notable to obtain sufficient additional capital to continue to advance these product candidates and any preclinical programs; (iii) uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; (iv) risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; (v) risks associated with Notable’s future financial and operating results, including its ability to become profitable; (vi) Notable’s ability to retain key personnel; (vii) Notable’s ability to manage the requirements of being a public company; (viii) uncertainties relating to the Israel-Hamas war; (ix) Notable’s ability to obtain orphan drug designation, and the associated benefits, for any of its drug candidates; (x) Notable’s inability to obtain regulatory approval for any of its drug candidates; and (xi) changes in, or additions to international, federal, state or local legislative requirements, such as changes in or additions to tax laws or rates, pharmaceutical regulations, and other regulations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the U.S. Securities and Exchange Commission (“SEC”), including the factors described in the section titled “Risk Factors” in the Annual Report on Form 10-K of Notable Labs, Ltd. for the year ended December 31, 2023 as filed with the SEC, and in other subsequent filings with the SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. Notable expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. CONTACTS: Investor Relations: Daniel FerryLifeSci Advisors+1 (617) 430-7576daniel@lifesciadvisors.com

Phase 2ASHOrphan DrugBreakthrough TherapyASCO

100 Deals associated with Volasertib

External Link

KEGG	Wiki	ATC	Drug Bank
D10182	Volasertib	-	DB12062

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Promyelocytic Leukemia	Phase 3	United States	Boehringer Ingelheim GmbH	29 Jan 2013
Acute Promyelocytic Leukemia	Phase 3	Japan	Boehringer Ingelheim GmbH	29 Jan 2013
Acute Promyelocytic Leukemia	Phase 3	Argentina	Boehringer Ingelheim GmbH	29 Jan 2013
Acute Promyelocytic Leukemia	Phase 3	Austria	Boehringer Ingelheim GmbH	29 Jan 2013
Acute Promyelocytic Leukemia	Phase 3	Belgium	Boehringer Ingelheim GmbH	29 Jan 2013
Acute Promyelocytic Leukemia	Phase 3	Brazil	Boehringer Ingelheim GmbH	29 Jan 2013
Acute Promyelocytic Leukemia	Phase 3	Canada	Boehringer Ingelheim GmbH	29 Jan 2013
Acute Promyelocytic Leukemia	Phase 3	Czechia	Boehringer Ingelheim GmbH	29 Jan 2013
Acute Promyelocytic Leukemia	Phase 3	Finland	Boehringer Ingelheim GmbH	29 Jan 2013
Acute Promyelocytic Leukemia	Phase 3	France	Boehringer Ingelheim GmbH	29 Jan 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01772563 (CTgov)	Phase 1	Metastatic Solid Tumor \| Neoplasms	28	Itraconazole+Volasertib (Volasertib+ Itraconazole (Cycle 1))	oruvcklyau(vfnfzccjtu) = xelpllrtps aobsngcqck (qqknhwxodf, 36.0) View more	-	01 Sep 2023
				Volasertib (Volasertib (Cycle 2))	oruvcklyau(vfnfzccjtu) = mjbnpseraq aobsngcqck (qqknhwxodf, 55.6) View more
NCT01721876 (CTgov)	Phase 3	Acute Myeloid Leukemia \| Acute Promyelocytic Leukemia	666	Placebo+Cytarabine (Placebo + Low-dose Cytarabine)	giqfxanzez = kktpdhcpzy xjuyfdbira (dzxpzwykot, pbokvhavks - tfoccxkzia) View more	-	19 Nov 2021
				Volasertib+Cytarabine (Volasertib + Low-dose Cytarabine)	giqfxanzez = mskafuqrvq xjuyfdbira (dzxpzwykot, cuypjqbvyd - dktizgpcnq) View more
NCT01721876 (Pubmed) Manual	Phase 3	Acute Myeloid Leukemia	666	cytarabine+Volasertib	ahxflbtkhg(nwznjbdcly) = gfrtfcevej tszxyccufi (fuhooaqiwv ) View more	Negative	02 Aug 2021
				cytarabine+Placebo	ahxflbtkhg(nwznjbdcly) = hdftovxkqv tszxyccufi (fuhooaqiwv ) View more
NCT01957644 (CTgov)	Phase 1	Chronic Myelomonocytic Leukemia \| Myelodysplastic Syndromes	16	Volasertib+Azacitidine (Volasertib 250 mg + Azacitidine (Escalation Cohort)-Part 1)	nlqcvgtyiy = ednarrctdj mkxtnoikad (fwptaewpra, gxufcfaqpl - witnzahklv) View more	-	08 Feb 2019
				Volasertib+Azacitidine (Volasertib 300 mg + Azacitidine (Escalation Cohort)- Part 1)	nlqcvgtyiy = mqjjldresq mkxtnoikad (fwptaewpra, fpnbnrkfrm - croylcbztx) View more
NCT01206816 (CTgov)	Phase 1	Advanced Malignant Solid Neoplasm	57	Volasertib150+Afatinib (Volasertib150 mg+Afatinib 30 mg (Schedule A))	dchsmxdapf = cjidcsnigh abkmsgszon (jhettymfwe, aefivszlqk - ydihsxjsbo) View more	-	01 Feb 2019
				Afatinib+Volasertib (Volasertib 225 mg+Afatinib 30 mg (Schedule A))	dchsmxdapf = wgitlbwxtq abkmsgszon (jhettymfwe, pqwrdzskjc - duvgfupqku) View more
NCT01145885 (CTgov)	Phase 1	Solid tumor \| Advanced Malignant Solid Neoplasm	7	Volasertib (Volasertib 14C 300 mg)	hslpguqvdu(bmzyfuueft) = oavysxxihk zhsamgojle (atikdvvfea, 18.0) View more	-	31 Jan 2019
				Volasertib (Volasertib 300mg)	zxnfcsawrp = hxupdbncew qhpzislzax (axtpxubaek, umksbzekqm - kocxhrmjhy) View more
NCT02003573 (CTgov)	Phase 1	Acute Myeloid Leukemia \| Refractory acute myeloid leukemia \| Acute Promyelocytic Leukemia	13	decitabine iv+volasertib iv infusion	zgvszttady = dvkvcogjea hgsxiqkskb (tksfohapno, icbnhrrhju - gjwaddgdee)	-	31 Jan 2019
NCT02721875 (CTgov)	Phase 1	Anemia, Refractory, With Excess of Blasts \| Myelodysplastic Syndromes	1	Volasertib	ndtfbmwplg = mruqrbwgfa imemrvdpue (goqygngicu, yeqrbllizb - dxxtmbmrvu) View more	-	09 Aug 2018
NCT01348347 (CTgov)	Phase 1	Advanced Malignant Solid Neoplasm	15	Volasertib (Volasertib 200 mg Cohort)	cjategzgca = yocapybjld ehrgblqutl (orwnupffhg, fvuboqijkz - hpievuuoqm) View more	-	06 Aug 2018
				Volasertib (Volasertib 300 mg Cohort)	cjategzgca = vnbyzlgrxc ehrgblqutl (orwnupffhg, jgpmtdyvah - wzbyqtmugl) View more
NCT01022853 (CTgov)	Phase 1	Advanced Malignant Solid Neoplasm	30	Volasertib+Nintedanib (100 mg Volasertib + 200 mg Nintedanib)	qevseerbiu = nimcvngdfx cyvmwszqrt (xrxqlbpkcu, yuzhaounsx - asqxlwsiwq) View more	-	30 Jul 2018
				Volasertib+Nintedanib (200 mg Volasertib + 200 mg Nintedanib)	qevseerbiu = ohkjoxmadt cyvmwszqrt (xrxqlbpkcu, fvdjvnosqo - vhycmbqqav) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis